Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LAURION Intercepts of 37.70 g/t Gold over 0.50 m, 6.60 g/t Gold over 1.00 m (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News NewAmsterdam Pharma Equity Warrant Exp 15th Nov 2027 NAMSW

NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:NAMSW)

NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

GlobeNewswire 4 hours ago

NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

GlobeNewswire 1 day ago

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia

GlobeNewswire 1 day ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 5 days ago

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH

GlobeNewswire November 20, 2024

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024

GlobeNewswire November 18, 2024

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results

GlobeNewswire November 6, 2024

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 1, 2024

NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November

GlobeNewswire October 28, 2024
View More News ››

Opinion & Analysis (NDAQ:NAMSW)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:NAMSW)

Be the first to post on this bullboard.

Calima Energy Ord Shs

Calima Energy Ord Shs

Calima Energy Limited is an Australia-based production-focused energy company. The Company is engaged in the exploration and ...
View More »